Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 16:05 ET | Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
April 17, 2024 16:05 ET | Serina Therapeutics, Inc.
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
March 26, 2024 17:04 ET | Serina Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
November 17, 2023 08:00 ET | Serina Therapeutics, Inc.
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a...